Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BIIB Biogen
283.630-3.890-1.35%
Close
02/03 16:00 ET
283.500-0.130-0.05%
Post Mkt Price 02/03 17:02 ET
High
291.100
Open
288.570
Turnover
224.90M
Low
282.520
Pre Close
287.520
Volume
789.15K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Biogen Inc. Stock Underperforms Friday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) slid 1.35% to $283.63 Friday, on what proved to be an all-around poor tr
Analysts' Top Healthcare Picks: Biogen (BIIB), Cytokinetics (CYTK)
Biogen Inc. Stock Underperforms Thursday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) slid 1.40% to $287.52 Thursday, on what proved to be an all-around mixed
U.K. Pharma Lobby Urges Govt. to Halt Plans to Raise Revenue Recovery Rates
Anavex Gains as Trial for Rett Syndrome Candidate Exceeds Enrollment Target
Biogen Inc. Stock Rises Wednesday, Still Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) inched 0.24% higher to $291.60 Wednesday, on what proved to be an all-ar
Biogen Inc. Stock Rises Tuesday, Outperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) advanced 1.73% to $290.90 Tuesday, on what proved to be an all-around po
Immunic Adds 14% as Wedbush Initiates With Bullish View on Lead Asset
UniQure Inks Licensing Deal for Gene Therapy Candidate Targeting ALS
Eisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan
05:15 AM EST, 01/31/2023 (MT Newswires) -- Japanese health authorities awarded priority review status to the application filed by Eisai (TYO:4523) for the manufacturing and marketing of lecanemab, an
Company Overview
More
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
CEO： Mr. Christopher A. Viehbacher
Market： NASDAQ
Listing Date： 09/17/1991
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet